Imatinib Tad

Imatinib, the active ingredient in Imatinib Tad, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for chronic myeloid leukemia, Philadelphia‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients. GNH USA supplies Imatinib Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways, providing targeted antineoplastic therapy. - Chronic myeloid leukemia (CML): suppresses BCR‑ABL‑driven proliferation and induces cytogenetic remission. - Philadelphia‑positive acute lymphoblastic leukemia (ALL): blocks the same BCR‑ABL fusion protein, improving remission rates. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT and PDGFR signaling, reducing tumor growth and recurrence.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often of the ankles. - Muscle cramps: intermittent painful contractions. - Fatigue: generalized tiredness. - Diarrhea: loose stools, sometimes watery. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Neutropenia: marked reduction in white blood cells, increasing infection risk. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Cardiac failure: reduced left‑ventricular ejection fraction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary hypertension: elevated pressure in lung arteries. - Hemorrhage: abnormal bleeding, especially gastrointestinal.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly. - Blood count monitoring: perform complete blood counts weekly during the first month, then periodically. - Liver function assessment: check transaminases and bilirubin before treatment and during therapy. - Cardiac evaluation: obtain baseline ECG and echocardiogram if cardiac risk factors exist. - Pregnancy considerations: avoid use in pregnancy unless benefits outweigh risks; discuss contraception. - Hepatic impairment dosing: adjust dose in moderate to severe liver disease. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with other medicines that affect its metabolism or pharmacodynamics.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug concentrations. - Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Digoxin: potential increase in serum digoxin; check levels regularly.